fingolimod hydrochloride has been researched along with cobaltous chloride in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (cobaltous chloride) | Trials (cobaltous chloride) | Recent Studies (post-2010) (cobaltous chloride) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 1,935 | 8 | 737 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ab Rahim, S; Abdul Hamid Hasani, N; Hanafi, NI; Md Noor, J; Mohamed, AS; Sheikh Abdul Kadir, SH; Siran, R | 1 |
1 other study(ies) available for fingolimod hydrochloride and cobaltous chloride
| Article | Year |
|---|---|
Ursodeoxycholic acid protects cardiomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1α and p53 protein.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Cell Survival; Cells, Cultured; Cobalt; Fingolimod Hydrochloride; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Myocytes, Cardiac; Pertussis Toxin; Protective Agents; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Tumor Suppressor Protein p53; Ursodeoxycholic Acid | 2017 |